EASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis
Data arrives as drugmakers race to bring successors to popular obesity therapies like semaglutide and tirzepatide to market.
Read the full article on the original site.
Read Full Article